Abstract Library

#4651 Neuroendocrine hyperplasia of infancy (NEHI) vs. diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): What is the difference?

Introduction: Neuroendocrine Hyperplasia of Infancy (NEHI) is a rare disease that belongs to the group of interstitial lung disease in children; characterised by hypoxemia, tachypnoea, and respiratory distress, often misdiagnosed as reactive airway disease or bronchiolitis. The diagnosis relies on histologic evaluation. We describe the clinical presentation and paraclinical characteristics of paediatric patients with NEHI.

Conference:

Presenting Author:

Authors: González Devia D, Restrepo Gualteros S, Ortiz Pérez M, Fernández Hernández B,

Keywords: Neuroendocrine Hyperplasia of Infancy, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, child,

#4526 The relationship between adherence to traditional Chinese medicine and disease progression in type 1 gastric neuroendocrine tumours: A case report

Introduction: Type 1 gastric neuroendocrine tumours (g-NETs) have a high recurrence risk after endoscopic resection, underscoring the need for regular endoscopic follow-up. Our research hints that Traditional Chinese Medicine (TCM) could help lower recurrence rates.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Cheng Z, Yu F, Chen R, Chen X,

Keywords: type 1 gastric neuroendocrine tumour, Traditional Chinese Medicine, regular follow-up, case report,

#4483 Metabolic parameters and visceral adiposity index in type 1 gastric neuroendocrine tumours: A single-centre cross-sectional study

Introduction: Studies have shown that the accumulation of visceral fat and the occurrence of metabolic syndrome (MetS) lead to disruptions in immune-metabolic crosstalk, contributing to the development and progression of autoimmune diseases and well-differentiated gastric neuroendocrine tumours (gNETs).

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Chen R, Wang Y, Wang Y,

Keywords: Type 1 gastric neuroendocrine tumour, Metabolic Syndrome, Visceral Adiposity Index,

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4422 A case report of an undifferentiated neuroendocrine carcinoma with an unknown primary site

Introduction: In the situation where the primary lesion remains unknown, high-grade poorly differentiated neuroendocrine carcinoma typically shows extensive metastasis at the time of clinical visit. Common metastatic sites include the liver, bones, lungs and brain, and the prognosis is extremely poor.

Conference:

Presenting Author:

Authors: Lv J, Tang Y,

Keywords: poorly differentiated neuroendocrine carcinoma, unknown primary origin,